Azitra, Inc.

AZTR Healthcare Biotechnology

Azitra, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $7,500.00, down 98.9% from fiscal 2023. In the quarter to June 2026, EPS grew 85.6% and free cash flow fell 19.6%, each against the same quarter a year earlier.

0.07 0.00 0.00%
Market cap
$4.3M
P/E
1.0×
Fwd P/E
−0.1×
Dividend yield
—
F-score
3/9
Altman Z
−14.66
Beneish M
13.02
Dividend safety
n/a
Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
— — 3 3 —
P/E ratio
0.00 0.00 0.00 0.00 —
P/S ratio
14.28 14.28 10.56 2.80 —
Altman Z-Score
— — (16.02) (14.66) —
Altman Z″-Score (non-manufacturers)
(16.73) (24.96) (38.17) (28.50) —
P/FCF ratio
0.00 0.00 0.00 0.00 —
Beneish M-Score
— (2.16) (5.04) 13.02 —
P/Operating CF
(4.01) (4.01) (2.85) (0.63) —
P/B ratio
0.00 0.00 2.49 0.28 —
EV/Sales
28.82 28.82 7.98 (5.04) —
EV/EBITDA
0.00 0.00 0.00 0.29 —
EV/FCF
(1.05) (1.05) (0.71) 0.28 —
Current Ratio
7.02 1.86 1.58 3.80 2.83
Net Debt/EBITDA
(2.92) (0.34) 0.27 0.45 0.20
Debt/Equity
(1.35) (0.18) 0.01 0.00 0.00
ROE
0.00% 43.37% 75.80% (208.27%) (230.65%)
ROA
0.00% (154.87%) (205.80%) (143.78%) (176.93%)
ROIC
0.00% 0.00% (407.29%) (595.10%) (395.49%)
Return on Tangible Assets
(142.34%) (487.14%) (769.50%) (198.99%) (438.23%)
Average Days of Receivables
1,108.94 342.12 118.92 4,959.13 0.00
Earnings Yield
(129.73%) (129.73%) (155.63%) (552.83%) —
Free Cash Flow Yield
(192.37%) (192.37%) (106.01%) (651.14%) —
Free Cash Flow per Share
(0.67) (1,638.92) (222.63) (18.49) (2.34)
Book value per Share
(2.13) (6,841.57) 84.44 9.98 0.78
Free Cash Flow
(8.07) (8.69) (7.68) (10.56) (11.41)
EV/EBIT
0.00 0.00 0.00 0.27 —
Other line items

Show all line items

Columns are period end dates